John Aitken, a laboratory scientist from New Zealand, discusses Mycobacterium avium ssp paratuberculosis from a microbiological perspective. Find out what we know about this organism and how it behaves. See never before released photos of the organism, learn why Mr. Aitken calls this “Son of MAP” and how his research will help Crohn’s disease patients.
[button link=”http://humanpara.org/map-research-john-aiken/” type=”big” color=”orange”] Watch the Video[/button]
Dr. William Chamberlin discusses the dysfunctional immune response of Crohn’s disease patients and a new treatment that is in development to remedy this genetic malady. EpiBro is a synthetic steroid, and it attempts to fix the dysfunction in Crohn’s disease by enhancing the innate immune response. Dr. Chamberlin terms it “Prednisone without the side effects.” Hear the story of how this drug, initially developed to treat AIDS infections, could now be utilized to help Crohn’s disease patients as well.
[button link=”http://humanpara.org/emerging-crohns-medical-treatments-dr-william-chamberlin” type=”big” color=”orange”] Watch the Video[/button]
Dr. Amy Hermon-Taylor talks about the MAP Vaccine that her father’s lab is developing. She gives a clear explanation of how the vaccine will work to treat Crohn’s disease patients and discusses the timeframe and steps required for approval. Includes engaging questions from the audience!
A welcome surprise to the symposium lineup, Dr. David Rubin, section chief of the department of gastroenterology at the University of Chicago Medical Center, discusses the current state of Crohn’s disease and outlines some of the available treatments. While he prescribes Anti-MAP therapy for some of his patients, he takes an individualistic approach to care, utilizing all treatment available to manage his patients’ disease. Interesting information about the role of the gut microbiome, the genetic profile of Crohn’s patients and how Dr. Rubin became interested in gastroenterology are included. He admits that the search for a cure should be a goal of current IBD research. Don’t miss the insightful audience questions!
[button link=”http://humanpara.org/the-current-state-of-crohns-treatment-dr-david-rubin” type=”big” color=”orange”] Watch the Video[/button]
We are at the dawning of a new era in the use of antibiotics.
For some 20 years there have been attempts to use antibiotics in the treatment of Crohn’s disease. Although most trials have delivered mixed results, this direction has been reinforced by the association of Mycobacterium avium ssp paratuberculosis (MAP) with Crohn’s disease.
The main principle of judicious and effective antibiotic usage has been the targeting of the suspected pathogen with a therapy that is both specific and directed. This has been a difficult job, as there has been, up to now, no protocol that will ensure the reliable isolation of the pathogen from the patient. The model that is used for new compounds against MAP-associated organisms is directly related to the proven therapies for tuberculosis, and this has been a wise model to follow.
[button link=”http://thecrohnsinfection.org/john-aitken-antibiotics/” type=”big”] Read the Full Article[/button]
